9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)

ConditionMetastatic Non-squamous Non Small Cell Lung CancerEstimated Enrollment: 201Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CBP08-02Study First Received: July 17, 2009Last Updated: July 29, 2013Estimated Primary Completion Date: July 2013Primary Outcome Measures:The primary efficacy endpoint is Progression free survival, analyzed in the treated population. PFS is assessed from randomization until either tumor progression, as per RECIST criteria, or until death due to any reason.|Objective response rate (CR + PR): response is to be assessed according to RECIST criteria (see Section 7.1), with...

Continue reading

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

ConditionNeoplasmsEstimated Enrollment: 96Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: A6181084Study First Received: September 10, 2007Last Updated: April 7, 2011Estimated Primary Completion Date: April 2010Primary Outcome Measures:To determine maximally tolerated dose of SU011248 (dosed continuously or on a 2/1 Schedule) when given in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin.|To evaluate the plasma pharmacokinetics of SU011248 and its metabolite, SU012662 in addition to pemetrexed, SU011248 and pemetrexed/cisplatin, and SU011248 and pemetrexed/carboplatin when these drugs are co-administered.|To preliminarily assess the antitumor...

Continue reading

Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.

ConditionLung Cancer|Mesothelioma|Pancreas Cancer|Gastric CancerEstimated Enrollment: 40Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive CareStudy ID Numbers: CE148/2012Study First Received: March 1, 2014Last Updated: July 30, 2015Estimated Primary Completion Date: April 2014Primary Outcome Measures:percentage of cancer patients that accept and attend the early palliative care programme|percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologistsSponsors and Collaborators:Arcispedale Santa Maria Nuova-IRCCSResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02078700...

Continue reading

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

ConditionAdvanced Esophageal Cancers|Primary Small Cell Lung Cancers|Non-Small-Cell Lung Carcinoma|Pleural Mesotheliomas|Cancers of Non-thoracic Origin With Metastases to the Lungs or PleuraEstimated Enrollment: 34Age Group: 18 Years to 65 Years   (Adult)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: TreatmentStudy ID Numbers: 020205|02-C-0205Study First Received: May 21, 2002Last Updated: April 19, 2017Estimated Primary Completion Date: October 8, 2008Primary Outcome Measures:Pharmacokinetics and toxicity profileSponsors and Collaborators:National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00037817...

Continue reading

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

ConditionLung Cancer|Malignant Mesothelioma|Metastatic CancerEstimated Enrollment: nullAge Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: 000088|00-C-0088|CDR0000067718Study First Received: July 11, 2001Last Updated: March 14, 2012Estimated Primary Completion Date: nullPrimary Outcome Measures:Sponsors and Collaborators:National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00020124...

Continue reading

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

ConditionAbdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal NeoplasmEstimated Enrollment: 188Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 000069|00-C-0069Study First Received: February 3, 2000Last Updated: October 19, 2015Estimated Primary Completion Date: August 2009Primary Outcome Measures:Number of Participants With Disease-free Survival|Number of Participants With a Response|Number of Participants With Adverse Events|Percentage of Participants Who Had Paclitaxel and 5-fluorouracil (5-FU) Analysis Performed|Quality of Life Questionnaire Score|Signal Transduction Pathways in Tumor Tissue Versus Normal TissueSponsors and Collaborators:National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Result Received: August 30, 2011Website Link:...

Continue reading

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

ConditionMesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung CancerEstimated Enrollment: 6Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic ScienceStudy ID Numbers: MORAb-009-006Study First Received: January 7, 2011Last Updated: September 28, 2016Estimated Primary Completion Date: March 2013Primary Outcome Measures:Primary Objective: determine biodistribution of radiolabeled amatuximab in tumor and nontumor tissue|Secondary objectives: determine the safety of a single IV of Indium-CHX-A amatuximab|Pharmacokinetic and serum levels|uptake of Indium-CHX-A amatuximab|occurrence of HACA|correlate shed serum mesothelin to imagingSponsors and Collaborators:MorphotekResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01521325...

Continue reading

Alanosine in Treating Patients With Cancer

ConditionLung Cancer|Malignant Mesothelioma|Pancreatic Cancer|SarcomaEstimated Enrollment: nullAge Group: 13 Years and older   (Child, Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: SALMEDIX-SDX-102-01|MSKCC-03029|CDR0000304677Study First Received: June 5, 2003Last Updated: June 25, 2013Estimated Primary Completion Date: December 2005Primary Outcome Measures:Sponsors and Collaborators:Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00062283...

Continue reading

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

ConditionNon-small Cell Lung Cancer|Mesothelioma|Lung NeoplasmsEstimated Enrollment: 31Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 10426|H3E-MC-JMHXStudy First Received: April 18, 2006Last Updated: June 10, 2010Estimated Primary Completion Date: March 2009Primary Outcome Measures:Overview of Adverse Events|Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities|Pemetrexed Population Pharmacokinetics (PK): Clearance|Pemetrexed Population Pharmacokinetics: Volume of Distribution|Discontinuations Due to Adverse EventsSponsors and Collaborators:Eli Lilly and CompanyResult Received: March 10, 2010Website Link: https://ClinicalTrials.gov/show/NCT00316225...

Continue reading

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

ConditionAdvanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous MesotheliomaEstimated Enrollment: 106Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02430|CDR0000069058|NCI-2710|UCCRC-11046A|11046A|2710|N01CM17102|P30CA014599Study First Received: December 7, 2001Last Updated: February 10, 2014Estimated Primary Completion Date: May 2006Primary Outcome Measures:Time to disease progression|Complete response rate|Objective response rate (complete and partial response)|Rate of disease stabilization|Overall survival|Incidence of adverse events graded according to NCI CTCAE version 3.0Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00027703...

Continue reading